| 重型地中海贫血的移植进展 |
| |
| 引用本文： | 黄楚雯,江华. 重型地中海贫血的移植进展[J]. 中国当代儿科杂志, 2020, 22(1): 77-81. DOI: 10.7499/j.issn.1008-8830.2020.01.015 |
| |
| 作者姓名： | 黄楚雯 江华 |
| |
| 作者单位： | 黄楚雯, 江华 |
| |
| 摘 要： | 地中海贫血是因调节血红蛋白的基因突变导致珠蛋白链形成障碍的遗传性血液疾病。目前异基因造血干细胞移植是公认的唯一治愈手段，其经历了预处理方案的演进，供体及移植物来源的对比选择等阶段，现生存情况已得到提高。该文回顾了地中海贫血移植的发展过程及研究进展，以期给临床提供更合适的治疗选择决策。
|
| 关 键 词： | 地中海贫血 造血干细胞移植 儿童 |
| 收稿时间： | 2019-09-12 |
| 修稿时间： | 2019-12-12 |
Research advances in transplantation for thalassemia major |
| |
| HUANG Chu-Wen,JIANG Hua. Research advances in transplantation for thalassemia major[J]. Chinese journal of contemporary pediatrics, 2020, 22(1): 77-81. DOI: 10.7499/j.issn.1008-8830.2020.01.015 |
| |
| Authors: | HUANG Chu-Wen JIANG Hua |
| |
| Affiliation: | HUANG Chu-Wen, JIANG Hua |
| |
| Abstract: | Thalassemia is an inherited blood disorder caused by disordered globin chain synthesis due to mutations in the regulatory genes for hemoglobin. At present, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is recognized as the only curative method for treatment. Through the revolution of pretransplantation regimens and selection of donor and source of stem cells, patients' survival has been greatly improved. This article reviews the development of transplantation for thalassemia and related research advances, in order to provide suitable treatment options for clinical application. |
| |
| Keywords: | Thalassemia|Hematopoietic stem cell transplantation|Child |
| 本文献已被 CNKI 维普 等数据库收录！ |
| 点击此处可从《中国当代儿科杂志》浏览原始摘要信息 |
|
点击此处可从《中国当代儿科杂志》下载全文 |
|
